Alnylam Pharmaceuticals Inc. agreed to drop its infringement lawsuit over Moderna Inc.’s Covid-19 vaccine after a federal judge’s unfavorable patent ruling last week, even as their more recent related case will continue.
Alnylam determined that the court’s definitions of three disputed constructions affecting all asserted claims from the two vaccine-related patents “preclude it from obtaining a judgment in its favor with respect to infringement” by Moderna’s Spikevax “as currently formulated,” according to a stipulation and joint motion for entry of final judgment of non-infringement filed Aug. 25 in the US District Court for the District of Delaware.
The agreement, which …
Read full article
